A randomized double-blind placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.